1. Home
  2. TNGX vs AMCX Comparison

TNGX vs AMCX Comparison

Compare TNGX & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • AMCX
  • Stock Information
  • Founded
  • TNGX 2014
  • AMCX 1980
  • Country
  • TNGX United States
  • AMCX United States
  • Employees
  • TNGX N/A
  • AMCX N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • AMCX Cable & Other Pay Television Services
  • Sector
  • TNGX Health Care
  • AMCX Telecommunications
  • Exchange
  • TNGX Nasdaq
  • AMCX Nasdaq
  • Market Cap
  • TNGX 413.6M
  • AMCX 412.5M
  • IPO Year
  • TNGX N/A
  • AMCX 2011
  • Fundamental
  • Price
  • TNGX $3.04
  • AMCX $9.38
  • Analyst Decision
  • TNGX Strong Buy
  • AMCX Hold
  • Analyst Count
  • TNGX 8
  • AMCX 3
  • Target Price
  • TNGX $13.14
  • AMCX $9.33
  • AVG Volume (30 Days)
  • TNGX 1.5M
  • AMCX 577.7K
  • Earning Date
  • TNGX 11-06-2024
  • AMCX 02-07-2025
  • Dividend Yield
  • TNGX N/A
  • AMCX N/A
  • EPS Growth
  • TNGX N/A
  • AMCX N/A
  • EPS
  • TNGX N/A
  • AMCX 0.79
  • Revenue
  • TNGX $43,383,000.00
  • AMCX $2,500,857,000.00
  • Revenue This Year
  • TNGX $27.73
  • AMCX N/A
  • Revenue Next Year
  • TNGX N/A
  • AMCX N/A
  • P/E Ratio
  • TNGX N/A
  • AMCX $11.91
  • Revenue Growth
  • TNGX 15.67
  • AMCX N/A
  • 52 Week Low
  • TNGX $2.70
  • AMCX $7.08
  • 52 Week High
  • TNGX $13.01
  • AMCX $19.55
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 39.30
  • AMCX 51.11
  • Support Level
  • TNGX $2.72
  • AMCX $9.06
  • Resistance Level
  • TNGX $3.29
  • AMCX $9.51
  • Average True Range (ATR)
  • TNGX 0.30
  • AMCX 0.43
  • MACD
  • TNGX 0.07
  • AMCX -0.06
  • Stochastic Oscillator
  • TNGX 32.08
  • AMCX 35.58

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached nearly 65 million pay-TV households in the US at the end of 2023. The firm also had nearly 11.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

Share on Social Networks: